Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged pimavanserin
Can MSN prevail on its patent appeal against Acadia for generic Nuplazid?

Acadia has been embroiled in a patent dispute with MSN Pharmaceuticals over a generic version of Acadia’s Parkinson’s Disease drug Nuplazid® (pimavanserin).  The lawsuit boiled down to a single dispute over a single legal issue concerning a single patent.  In December 2023, the district court ruled in favor of Acadia.  The case is now on appeal before the Federal Circuit. What are the chances of MSN prevailing on appeal? 

Read More
Markman AdvisorsZachary Silbersher, Silbersher, MSN Pharmaceuticals, MSN, Acadia, Acadia Pharmaceuticals, Nuplazid, pimavanserin, double patenting, obviousness-type double patenting, safe harbor, patent, 740 patent, patent term adjustmentComment